# Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/camrelizumab-shr-1210-alone-or-in-combination-with-gemcitabine-plus-cisplatin/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Wenfeng Fang,Yunpeng Yang,Yuxiang Ma,Shaodong Hong,Lizhu Lin,Xiaohui He,Jianping Xiong,Ping Li,Hongyun Zhao,Yan Huang,Yang Zhang,Likun Chen,Ningning Zhou,Yuanyuan Zhao,Xue Hou,Qing Yang,Li Zhang |
| Citations | 508 |
| DOI | 10.1016/s1470-2045(18)30495-9 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2890100090 |
| PMID | 30213452 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Wenfeng Fang](https://scholariq.org/researchers/wenfeng-fang/)
- [Yunpeng Yang](https://scholariq.org/researchers/yunpeng-yang/)
- [Yuanyuan Zhao](https://scholariq.org/researchers/yuanyuan-zhao/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)

## Paper topics

- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.